Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

When Steroids Cause Psychosis

Jane P. Gagliardi, MD, MHS, Andrew J. Muzyk, PharmD, & Shannon Holt, PharmD  |  Issue: October 2010  |  October 1, 2010

Dr. Gagliardi is an assistant professor of psychiatry and behavioral sciences and assistant professor of medicine at Duke University School of Medicine in Durham, N.C. Dr. Muzyk is an assistant professor and Dr. Holt is a pharmacy resident at Campbell University School of Pharmacy and Health Sciences in Buies Creek, N.C.

References

  1. Bolanos SH, Khan DA, Hanczyc M, et al. Assessment of mood states in patients receiving long-term corticosteroid therapy and in controls with patient-rated and clinician-rated scales. Ann Allergy Asthma Immunol. 2004;92:500-505.
  2. Sirois F. Steroid psychosis: A review. Gen Hosp Psychiatry. 2003;25:27-33.
  3. Warrington TP, Bostwick JM. Psychiatric adverse effect of corticosteroids. Mayo Clin Proc. 2006;81:1361-1367.
  4. Brown ES, Suppes T, Khan DA, Carmody III TJ. Mood changes during prednisone bursts in outpatients with asthma. J Clinical Psychopharm. 2002;22:55-61.
  5. Brown WA, Johnston R, Mayfield D. The 24-hour dexamethasone suppression test in a clinical setting: Relationship to diagnosis, symptoms, and response to treatment. Am J Psychiatry. 1979;136:543-547.
  6. Naber D, Sand P, Heigl B. Psychopathological and neuropsychological effects of 8-days’ corticosteroid treatment. A prospective study. Psychoneuroendocrinology. 1996; 21:25-31.
  7. Brown ES, Woolston DJ, Frol A, et al. Hippocampal volume, spectroscopy, cognition, and mood in patients receiving corticosteroid therapy. Biol Psychiatry. 2004;55:538-545.
  8. Schatzberg AF, Rothschild AJ, Langlais PJ, et al. A corticosteroid/dopamine hypothesis for psychotic depression and related states. J Psychiatr Res. 1985;19:57-64.
  9. The Boston Collaborative Drug Surveillance Program. Acute adverse reactions to prednisone in relation to dosage. Clin Pharmacol Ther. 1972;13:694-698.
  10. Brown ES, Stuard G, Liggin JD, et al. Effect of phenytoin on mood and declarative memory during prescription corticosteroid therapy. Bio Psychiatry. 2005;57:543-548.
  11. Brown ES, Frol AB, Khan DA, et al. Impact of levetiracetam on mood and cognition during prednisone therapy. Eur Psychiatry. 2007;22:448-452.
  12. Brown ES, Frol A, Bobadilla L, et al. Effect of lamotrigine on mood and cognition in patients receiving chronic exogenous corticosteroids. Psychosomatics. 2003;44:204-208.
  13. Falk WE, Mahnke MW, Poskanzer DC. Lithium prophylaxis of corticotropin-induced psychosis. JAMA. 1979;241:1011-1012.
  14. Goldman LS, Goveas J. Olanzapine treatment of corticosteroid-induced mood disorders. Psychosomatics. 2002; 43:495-497.
  15. Brown ES, Khan DA, Suppes T. Treatment of corticosteroid-induced mood changes with olanzapine. Am J Psychiatry. 1999;156:968.
  16. Brown ES, Chamberlain W, Dhanani N, et al. An open-label trial of olanzapine for corticosteroid-induced mood symptoms. J Affect Disord. 2004;83:277-281.
  17. Budur K, Pozuelo L. Olanzapine for corticosteroid-induced mood disorders. Psychosomatics. 2003;44:353.
  18. Herguner S, Bilge I, Yavuz Yilmaz A, et al. Steroid-induced psychosis in an adolescent: Treatment and prophylaxis with risperidone. Turk J Pediatr. 2006;48:244-247.
  19. DeSilva CC, Nurse MC, Vokey K. Steroid-induced psychosis treated with risperidone. Can J Psychiatry. 2002;47: 388-389.
  20. Kato O, Misawa H. Steroid-induced psychosis treated with valproic acid and risperidone in a patient with systemic lupus erythematosus. Prim Care Companion J Clin Psychiatry. 2005;7:312.
  21. Kramer TM, Cottingham EM. Risperidone in the treatment of steroid-induced psychosis. J Child Adolesc Psychopharmacol. 1999;9:315-316.
  22. Siddiqui Z, Ramaswamy S, Petty F. Quetiapine therapy for corticosteroid-induced mania. Can J Psychiatry. 2005; 50:77-78.
  23. Ahmad M, Rasul FM. Steroid-induced psychosis treated with haloperidol in a patient with active chronic obstructive pulmonary disease [letter]. Am J Emergency Med. 1999;17:735.
  24. Bloch M, Gur E, Shalev A. Chlorpromazine prophylaxis of steroid-induced psychosis. Gen Hosp Psychiatry. 1994; 16:42-44.
  25. Boehm G, Racoosin JA, Laughren TP, Katz R. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004; 27:596-601.
  26. Siegal FP. Lithium for steroid-induced psychosis. N Engl J Med. 1978;299:155-156.
  27. Goggans FC, Weisberg LJ, Koran LM. Lithium prophylaxis of prednisone psychosis: A case report. J Clin Psychiatry. 1983;44:111-112.
  28. Sabet-Sharghi F, Hutzler JC. Prophylaxis of steroid-induced psychiatric syndromes. Psychosomatics. 1990;31:113-114.
  29. Merrill W. Case 35-1998: Use of lithium to prevent corticosteroid-induced mania. N Engl J Med. 1999;340:1123.
  30. Abbas A, Styra R. Valproate prophylaxis against steroid induced psychosis. Can J Psychiatry. 1994;39:188-189.
  31. Himelhoch S, Haller E. Extreme mood lability associated with systemic lupus erythematosus and stroke successfully treated with valproic acid. J Clin Psychopharmacol. 1996;16:469-470.
  32. Kahn D, Stevenson E, Douglas CJ. Effect of sodium valproate in three patients with organic brain syndromes. Am J Psychiatry. 1998;145:1010-1011.
  33. Wada K, Yamada N, Yamauchi Y, et al. Carbamazepine treatment of corticosteroid-induced mood disorder. J Affect Disord. 2001;65:315-317.
  34. Carlat DJ. The psychiatric review of symptoms: A screening tool for family physicians. Am Fam Phys. 1998;58:1617-1624.
  35. Preda A, Fazeli A, McKay BG, Bowers MB, Mazure CM. Lamotrigine as prophylaxis against steroid-induced mania. J Clin Psychiatry. 1999;60:708-709.
  36. Ginsberg DL, Sussman N. Gabapentin as prophylaxis against corticosteroid-induced mania. Can J Psychiatry. 2001;44:455-456.
  37. Pande AC, Crockatt JG, Janney CA, Werth JL, Tsaroucha G. Gabapentin in bipolar disorder: A placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group. Bipolar Disord. 2000; 2:249-255.
  38. Cheer SM, Wagstaff AJ. Quetiapine: A review of its use in the management of schizophrenia. CNS Drugs. 2004;18:173-199.
  39. Bowles TM, Levin GM. Aripiprazole: A new atypical antipsychotic drug. Ann Pharmacother. 2003;37:687-694
  40. Caley CF, Cooper CK. Ziprasidone: The fifth atypical antipsychotic. Ann Pharmacother. 2002;36:839-851
  41. Livingston MG. Risperidone. Lancet 1994;343:457-460.
  42. Fulton B, Goa KL. Olanzapine: A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs. 1997;53:281-298.

Page: 1 2 3 4 5 6 7 | Single Page
Share: 

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:LupusPsychosisSLESteroidSystemic lupus erythematosusSystemic sclerosis

Related Articles
    Course of treatment over time

    Case Report: The Hairdresser Who Couldn’t Comb Her Hair

    November 19, 2018

    Polymyalgia rheumatica (PMR) is an inflammatory rheumatic condition characterized by pain and morning stiffness at the neck, shoulders and hip girdle. It can be associated with giant cell arteritis (GCA); in fact, the two disorders may represent a continuum of the same disease process. This case describes a patient who initially refused treatment for PMR…

    Can Systemic Inflammation Influence Mood?

    August 17, 2015

    The Friday night press release: When a politician or any public figure needs to disclose unfavorable news, chances are they will release it sometime on a late Friday afternoon or evening, hoping that nobody is paying attention. In fact, this behavior was coined “the take out the trash day” on the television political drama, The…

    Depression in Rheumatoid Arthritis

    November 1, 2012

    Examining the psychological and health-related comorbidities of rheumatoid arthritis patients with depression

    Chronic Pain: The Psychiatric Perspective

    January 1, 2015

    Why rheumatic pain is more than a joint issue

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences